Weight loss peptides have moved from the margins of biohacking into mainstream medicine. With FDA-approved GLP-1 agonists producing 15-22% average body weight loss in clinical trials, peptide therapy is now the most effective pharmacological approach to weight management available.
But GLP-1s are only part of the picture. Growth hormone secretagogues, metabolic peptides, and targeted fat-loss compounds each offer distinct mechanisms that can be used alone or in combination for comprehensive weight loss support.
This guide breaks down which peptides actually work for weight loss, how they work, and the protocols that produce real results.
Tier 1: GLP-1 Receptor Agonists
Semaglutide
Semaglutide is the most clinically validated weight loss peptide available. Originally developed for type 2 diabetes (Ozempic), it gained FDA approval for weight management as Wegovy in 2021.
How it works: Semaglutide mimics the incretin hormone GLP-1, which slows gastric emptying, increases satiety signaling to the brain, and improves insulin sensitivity. The net effect is dramatically reduced appetite and caloric intake.
Clinical evidence: The STEP trial program demonstrated average weight loss of 14.9% of body weight over 68 weeks. Some participants lost over 20% of body weight.
Typical protocol:
- Start at 0.25mg weekly for 4 weeks
- Titrate to 0.5mg weekly for 4 weeks
- Increase to 1.0mg weekly, then 1.7mg and 2.4mg as tolerated
- Subcutaneous injection once weekly
Tirzepatide
Tirzepatide represents the next evolution in weight loss peptides. As a dual GIP/GLP-1 receptor agonist, it targets two incretin pathways simultaneously.
How it works: By activating both GIP and GLP-1 receptors, tirzepatide produces more potent appetite suppression, greater insulin sensitization, and enhanced fat oxidation compared to GLP-1 agonists alone.
Clinical evidence: The SURMOUNT-1 trial showed average weight loss of 22.5% at the highest dose — the most weight loss ever demonstrated by a pharmaceutical agent in clinical trials.
Typical protocol:
- Start at 2.5mg weekly for 4 weeks
- Titrate to 5mg weekly for 4 weeks
- Continue titrating through 7.5mg, 10mg, 12.5mg, and 15mg as tolerated
- Subcutaneous injection once weekly
Tier 2: Growth Hormone Secretagogues for Body Composition
Tesamorelin
Tesamorelin is unique among weight loss peptides because it specifically targets visceral fat — the metabolically dangerous fat surrounding internal organs.
How it works: As a GHRH analog, tesamorelin stimulates pulsatile growth hormone release from the pituitary. GH mobilizes visceral fat stores preferentially, reduces lipogenesis in the abdominal region, and improves metabolic markers.
Clinical evidence: FDA-approved for HIV-associated lipodystrophy, tesamorelin reduces visceral adipose tissue by 15-18% without significant lean mass loss. Off-label use for general visceral fat reduction shows similar results.
Typical protocol:
- 2mg subcutaneous injection daily
- Administered on an empty stomach (fasting for at least 2 hours)
- Best administered before bed or first thing in the morning
- Typical treatment duration: 12-26 weeks
Ipamorelin + CJC-1295
While not direct weight loss compounds, the ipamorelin/CJC-1295 combination improves body composition by enhancing GH-mediated fat oxidation and lean mass preservation.
How it works: Ipamorelin selectively stimulates GH release while CJC-1295 extends pulse duration. Elevated GH and IGF-1 increase lipolysis (fat breakdown), improve insulin sensitivity, and support lean mass retention during caloric restriction.
Typical protocol:
- Ipamorelin: 200-300mcg subcutaneous, 1-3 times daily
- CJC-1295 (no DAC): 100-200mcg subcutaneous, 1-3 times daily
- Best dosed before bed on an empty stomach
- Can also be dosed pre-workout and upon waking
Tier 3: Metabolic Peptides
MOTS-c
MOTS-c is a mitochondrial-derived peptide that enhances cellular metabolism at a fundamental level.
How it works: MOTS-c activates AMPK — the master metabolic switch — improving glucose uptake, fatty acid oxidation, and mitochondrial efficiency. It essentially helps cells burn fuel more effectively, supporting weight loss through enhanced metabolic rate.
Emerging evidence: Preclinical studies show MOTS-c prevents diet-induced obesity, improves exercise capacity, and enhances metabolic flexibility. Human clinical data is still limited but promising.
Typical protocol:
- 5-10mg subcutaneous injection, 3-5 times per week
- Can be taken at any time of day
- Often cycled: 4-8 weeks on, 4 weeks off
Choosing the Right Weight Loss Peptide Protocol
The best peptide for weight loss depends on your specific situation:
For significant weight loss (20+ lbs): Tirzepatide or semaglutide should be the primary compound. These produce the most clinically significant weight loss and have the strongest evidence base.
For visceral fat reduction: Tesamorelin is the targeted choice, especially when visceral fat is disproportionately high relative to overall body fat.
For body recomposition: The ipamorelin/CJC-1295 combination supports fat loss while preserving lean mass, making it ideal for individuals closer to their target weight who want to improve composition.
For metabolic optimization: MOTS-c addresses the cellular metabolic dysfunction that makes weight loss difficult, particularly for individuals with insulin resistance or metabolic inflexibility.
Stacking Strategies
Advanced protocols may combine peptides from different tiers:
- GLP-1 + GH secretagogue: Semaglutide or tirzepatide for appetite control combined with ipamorelin/CJC-1295 for lean mass preservation and overnight fat oxidation
- GLP-1 + tesamorelin: For individuals with high visceral fat who need both appetite control and targeted visceral fat mobilization
- Comprehensive stack: GLP-1 agonist + ipamorelin/CJC-1295 + MOTS-c for maximum metabolic support during active weight loss phases
What to Expect: Realistic Timelines
- Weeks 1-2: Appetite reduction (GLP-1s), improved sleep quality (ipamorelin)
- Weeks 4-8: Measurable weight loss begins, typically 1-2 lbs/week with GLP-1s
- Weeks 8-16: Significant body composition changes visible; visceral fat reduction measurable with tesamorelin
- Weeks 16-52: Continued weight loss toward plateau; most individuals reach maximum effect at 9-12 months with GLP-1s
Essential Monitoring
Any weight loss peptide protocol should include regular monitoring:
- Body composition: DEXA scans every 3-6 months (not just scale weight)
- Metabolic markers: Fasting glucose, insulin, HbA1c, lipid panel
- Hormonal status: Thyroid function, testosterone (weight loss can affect hormonal balance)
- GI tolerance: Nausea and GI side effects are common with GLP-1s and typically resolve with proper titration
- Nutritional status: Ensure adequate protein intake (1.2-1.6g/kg) to minimize lean mass loss
The Bottom Line
Peptide therapy for weight loss is not a shortcut — it is a clinical tool that works best when combined with proper nutrition, regular exercise, and medical supervision. GLP-1 agonists like semaglutide and tirzepatide represent the most effective options for significant weight loss. Growth hormone secretagogues and metabolic peptides provide complementary benefits for body composition optimization and metabolic health.
The key is matching the right peptide or combination to your specific goals, metabolic profile, and health status — ideally with guidance from a physician experienced in peptide therapy.